Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Clinical Obesity

Department of Clinical Sciences Malmö

Head: Martin Ridderstråle

The prevalence of obesity and type 2 diabetes (T2DM) is increasing worldwide. Although our therapeutic arsenal to beget these conditions and their consequences in the form of cardiovascular morbidity and mortality is increasing a lot still needs to be learned about the underlying mechanisms.

 

This project deals with clinical care and therapy of obesity and T2DM, collectively called "diabesity", as well as probing of underlying genetic mechanisms. We study variation in separate candidate genes such as PPAR−gamma, PGC1−alpha, CAPN10, FOXC2, APM1, ADPN, TCF7L2 and FTO, the transcription of these genes in skeletal muscle and adipose tissue biopsies or cells as well as changes in the whole transcriptome by cDNA−microarray. Our patient materials include both grown−ups and children.

 

At present assessing the global metabolic risk of an indivudual to develop cardiovascular disease and complications include clinical evaluation and laboratory tests. In the near future studies of the underlying genetic mechanisms of diabesity will contribute to this complex picture, not only to identify those at increased, but also decreased risk.